Peer-influenced content. Sources you trust. No registration required. This is HCN.

Articles related to CHECKPOINT INHIBITORS

MDLinx

Four Groundbreaking Clinical Studies Worth Your Attention

Cardiology September 20th 2022

Blood

Primary Central Nervous System Lymphoma

Hematology September 19th 2022

Journal of Clinical Oncology

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined with Pembrolizumab for Advanced Melanoma

Oncology, Medical September 12th 2022

Clinical Advances in Hematology & Oncology

Clinical Use of Measurable Residual Disease in CLL

Oncology, Medical August 22nd 2022

The Journal of Clinical Investigation (JCI)

Reversal of Viral and Epigenetic HLA Class I Repression in Merkel Cell Carcinoma (MCC)

Oncology, Medical August 22nd 2022

JCI Insight

Milademetan is a Highly Potent MDM2 Inhibitor in Merkel Cell Carcinoma (MCC)

Oncology, Medical August 22nd 2022